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Outer membrane protein size and LPS O-antigen
define protective antibody targeting to the
Salmonella surface
C. Coral Domínguez-Medina1,2,11, Marisol Pérez-Toledo 1,2,3,11, Anna E. Schager1,2, Jennifer L. Marshall1,
Charlotte N. Cook1,2, Saeeda Bobat1,2, Hyea Hwang4, Byeong Jae Chun 4, Erin Logan5, Jack A. Bryant2,
Will M. Channell1, Faye C. Morris2, Sian E. Jossi1, Areej Alshayea1, Amanda E. Rossiter2, Paul A. Barrow6,
William G. Horsnell5, Calman A. MacLennan7, Ian R. Henderson2, Jeremy H. Lakey8, James C. Gumbart9,
Constantino López-Macías 3, Vassiliy N. Bavro 10✉ & Adam F. Cunningham1,2✉
Lipopolysaccharide (LPS) O-antigen (O-Ag) is known to limit antibody binding to surface
antigens, although the relationship between antibody, O-Ag and other outer-membrane
antigens is poorly understood. Here we report, immunization with the trimeric porin OmpD
from Salmonella Typhimurium (STmOmpD) protects against infection. Atomistic molecular
dynamics simulations indicate this is because OmpD trimers generate footprints within the
O-Ag layer sufficiently sized for a single IgG Fab to access. While STmOmpD differs from its
orthologue in S. Enteritidis (SEn) by a single amino-acid residue, immunization with
STmOmpD confers minimal protection to SEn. This is due to the OmpD-O-Ag interplay
restricting IgG binding, with the pairing of OmpD with its native O-Ag being essential for
optimal protection after immunization. Thus, both the chemical and physical structure of O-
Ag are key for the presentation of specific epitopes within proteinaceous surface-antigens.
This enhances combinatorial antigenic diversity in Gram-negative bacteria, while reducing
associated fitness costs.
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Antibodies to the Gram-negative bacterial surface,induced after natural infection or vaccination, savemillions of lives each year, and typically function before
disease develops, reducing the need to use antibiotics and the
development of antimicrobial resistance. After natural infec-
tion, the greatest level of protection is typically against the
infecting strain, yet this is unsatisfactory for protection after
vaccination, where wide-ranging immunity to multiple, related
pathogens is clearly desirable. Achieving this is not always
straightforward as shown by the nature of extant vaccines
against Gram-negative bacteria. The only licensed single-
antigen vaccines against diseases caused by such bacteria are
based on capsular polysaccharides. When capsules are not
utilized, or not available, then vaccines become increasingly
antigenically complex, containing a mixture of purified anti-
gens, such as the Bexsero vaccine to meningococcus serotype B
or the acellular pertussis vaccine1,2. Even more antigenically
complex are vaccines based on attenuated organisms, which
offer the greatest breadth of antigen inclusion, but with little
empirical rationalization as to which antigens are protective.
This highlights our limited understanding of how protective
antibodies interact with the bacterial surface.
To understand how antibodies interact with the Gram-negative
bacterial surface, it is essential to consider the relationship
between antibodies, LPS, and protein antigens. LPS consists of a
conserved lipid A moiety and core oligosaccharide. In addition, it
typically has a polysaccharide side chain that varies between
different bacterial serotypes. This polysaccharide O-antigen (O-
Ag) made up of varying numbers of repeats, sometimes > 100 in
number, restricts access of molecules to the bacterial surface3. The
consequence is that the millions of molecules of LPS found in
each cell provide a formidable barrier to limit antibody access to
the bacterial surface. Furthermore, LPS O-Ag can show sig-
nificant structural variation even between closely related bacteria.
For instance, different serovars of Salmonella express different
O-Ag, such that Salmonella Typhimurium (STm) is partly
defined by their possession of the O:4 antigen, whereas S.
Enteritidis (SEn) is partly defined by the O:9 antigen.
In sub-Saharan Africa, invasive nontyphoidal salmonellosis
(iNTS) is primarily caused by STm and SEn4–7. Antibodies to
these strains strongly correlate with protection against invasive
disease, and because of the devastating impact of iNTS there is
an urgent need for a vaccine8. Achieving this would be greatly
aided by understanding why some antigens are protective and
others are not. Two frequently recognized cell-surface proteins
are OmpA and OmpD. OmpA is a monomeric protein that is a
common target of antibody after infection in mice and humans,
and OmpD is found in the cell envelope in trimeric form9. Both
antigens are highly conserved across Gram-negative bacteria,
particularly within the same genus, meaning that an antibody to
such a protein from one serovar may cross-protect against
another. Previously, using a number of model systems, we had
identified that IgG antibodies to the porin protein OmpD can
offer cell-dependent or complement-dependent protection10,11.
Unexpectedly, not all IgG isotypes offer equivalent protection,
and this correlated to the level of access of antibodies to bind
OmpD in the presence of O-Ag12. This suggests that O-Ag
influences the level of binding of IgG to the bacterial surface. In
this study, we tested this concept by examining the capacity of
antibody to OmpD from STm (STmOmpD) to cross-protect
against SEn, which contains a near-identical OmpD that differs
by a single amino acid. Our findings suggest that how small
changes in proteinaceous surface antigens of Gram-negative
bacteria can combine with O-Ag to maximize antigen diversity
within a single species, and have implications for generating
vaccines offering multi-serovar protection.
Results
STmOmpD induces protective antibody responses. Wild-type
(WT) mice were immunized twice with 20 μg of purified
STmOmpD (Supplementary Fig. 1a and ref. 12) in the absence of
additional adjuvant. The induced anti-STmOmpD IgG bound to
the surface of two different isolates of STm: the model laboratory
strain SL1344 and a representative invasive African isolate of
STm, D23580, which was originally isolated from an African
patient13 (Fig. 1a). WT mice immunized twice with 20 μg of
STmOmpD and challenged intraperitoneally (i.p.) with STm
D23580 for 24 h had a ≥ 100-fold median reduction in their
bacterial burdens in the liver and spleen, and a near-10,000-fold
reduction in the median bacterial numbers in the blood (Fig. 1b).
Similar results were observed for the laboratory strain SL1344
(Supplementary Fig. 1b). To assess whether anti-STmOmpD
antibody alone was sufficient to promote bacterial killing, bacteria
were opsonized with complement-inactived anti-STmOmpD or
control sera prior to infection. This showed that opsonization
with anti-STmOmpD sera resulted in an ~100-fold reduction in
bacterial numbers post infection (Fig. 1c). We then assessed if
anti-STmOmpD sera could kill bacteria in a well-established
serum bactericidal assay (SBA), which uses human sera depleted
of anti-STm antibodies, as a source of complement14. In these
experiments, anti-STmOmpD antibodies enhanced complement-
dependent killing, whereas sera from control mice did not
(Fig. 1d). Purified OmpD had low levels of co-purifying LPS
(typical levels of LPS of ≤ 2 endotoxin units (EU) per 10 μg of
porin by limulus assay), but some contaminating LPS, and the
immunodominant protective O-Ag, could remain. To control for
antibodies generated to residual O-Ag present in the OmpD being
responsible for these effects, we immunized mice with OmpD
purified from a triple-mutant strain of STm that lacks OmpF,
OmpC, and O-Ag. Mice immunized with this OmpD exhibited
similar levels of protection (Supplementary Fig. 1c). Therefore,
anti-STmOmpD antibodies can reduce bacterial burdens in the
liver, spleen, and blood after infection with laboratory and clinical
strains of STm.
STmOmpD immunization confers minimal cross-protection to
SEn. The two most commonly identified iNTS isolates found in
sub-Saharan Africa are STm and SEn in which OmpD differs by a
single amino acid, a substitution of an alanine in STmOmpD at
position 263 to a serine in SEn (Fig. 2a; Supplementary Fig. 2).
Moreover, anti-STmOmpD antibodies had similar levels of
binding to purified porins from STm and SEn, indicating that
there are multiple shared epitopes present between these proteins
(Fig. 2b). Therefore, it was anticipated that immunization with
STmOmpD would confer cross-protection against SEn, enabling
its use within a multivalent vaccine. Mice were immunized twice
with 20 μg of STmOmpD before challenge with STm or SEn.
Immunization with STmOmpD induced statistically significant
protection in both groups. However, while there was a near-100-
fold reduction in immunized mice challenged with STm, the
reduction in bacterial numbers in SEn-challenged mice was less
than fivefold (Fig. 2c). Therefore, a single amino-acid variation
associates with the loss of protection afforded by immunization
with STmOmpD.
Loss of O-Ag enhances efficacy of protection against SEn. The
significantly diminished cross-protection to SEn after immuni-
zation with STmOmpD was unexpected. One interpretation of
the reduced protection to SEn after immunization with
STmOmpD is that the A263S variation is within an immuno-
dominant epitope that is most readily accessible to IgG, and that
other conserved epitopes are less accessible. To determine if LPS
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O-Ag impaired binding of anti-STmOmpD IgG to SEn, plates
were coated with intact STm or SEn, or mutants that lack O-Ag
(wbaP−). Binding of anti-STmOmpD IgG to O-Ag-expressing
STm or O-Ag-deficient STm was similar, consistent with the
antibody having a solely proteinaceous target (Fig. 3a). In con-
trast, when the coating antigen used was whole WT SEn, then
antibody binding was dramatically lower than that observed for
the different STm strains (Fig. 3a). However, binding of anti-
STmOmpD IgG to O-Ag-deficient SEn was comparable with
STm. This suggests that additional, conserved, epitopes became
accessible to anti-STmOmpD IgG when O-Ag was absent. We
then examined whether this enhanced binding of antibody to O-
Ag-deficient SEn altered the bactericidal activity of anti-
STmOmpD antibodies. Anti-STmOmpD antibody was bacter-
icidal for STm, but not SEn (Fig. 3b). However, anti-STmOmpD
serum could promote killing of O-Ag-deficient STm and O-Ag-
deficient SEn bacteria. Consistent with this, in most mice
immunized with STmOmpD, O-Ag-deficient SEn was not
detectable at all (Fig. 3c). These experiments suggest that most
IgG that binds OmpD on O-Ag-expressing bacteria targets a
limited number of variable proteinaceous epitopes that include
A263S, whereas O-Ag occludes binding to the larger number of
epitopes conserved between the two proteins.
OmpD trimer size allows IgG access through the LPS barrier.
We next assessed where the critical A263S variation was located
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Fig. 2 Antibodies to STmOmpD offer limited cross-protection to SEn. a
Alignment of OmpD sequences from STm and SEn showing the site where
an alanine-to-serine substitution is observed at amino acid 263 of the
whole sequence. b Serum IgG titers to STm and SEn porins from WT NI
mice and mice immunized with STmOmpD as in Fig. 1a. Each point
represents the titers from one mouse. Data representative of two
experiments. c NI mice and mice immunized twice with 20 μg of
STmOmpD were challenged with 5 × 105 aroA− STm or SEn, and bacterial
numbers per organ enumerated 3 days later. Each point represents the
titers from one mouse. Data are representative of two individual
experiments. *P ≤ 0.05, **P ≤ 0.01 assessed by two-tailed Mann–Whitney
U test.
105
104
103
102Ig
G
 ti
te
rs
101
100
107
106
105
104
103
≤102
105
104
103
102Ig
G
 ti
te
rs
101
100
NI STmOmpD
Liver Spleen
NI STmOmpD
NI STmOmpD
NI STmOmpD
Anti-STm SL1344
STm SL1344
Time (min)
0
–3
–2
–1
0
Lo
g 
10
 c
ha
ng
e 
in
sa
lm
on
el
la
 
(C
FU
/m
l)
1
2
3
d
c
b
a
45 90 135 180
NHS HiS STmOmpD NI
Anti-STmOmpD
opsonized
Control Anti-STmOmpD
opsonized
Control
ST
m
 D
23
58
0/
tis
su
e
107
106
105
104
103
102
ST
m
 D
23
58
0/
liv
er
107
106
105
104
103
102S
Tm
 D
23
58
0/
sp
le
en
107
106
105
104
103
102
≤101ST
m
 D
23
58
0/
m
l b
lo
od
Anti-STm D23580
Fig. 1 STmOmpD induces antibody that can impair infection against STm.
a WT mice were primed and boosted i.p. with 20 μg of STmOmpD at days 0,
14, and 28, and sera obtained at day 35. Anti-STm (D23580 and SL1344) IgG
was assessed by ELISA. Each point represents titers from an individual mouse,
and is representative of three repeat experiments. b Bacterial numbers in the
liver, spleen, and blood of nonimmunized (NI) and WT mice immunized twice
(days 0 and 14) with 20 μg of STmOmpD and challenged with 1 × 105 STm
D23580 for 24 h. Each point represents bacterial numbers in one mouse.
c Mice were infected i.p. with 5 × 105 of either STm SL3261 or bacteria
previously opsonized with STmOmpD antibodies. Bacteria numbers were
quantified at day 3 from the spleen and liver. Data are representative of two
independent experiments. d Serum bactericidal assays using STm SL1344
with sera from NI mice or mice immunized as in a, supplemented with human
sera as a complement source with anti-STm-specific antibodies depleted.
Normal human serum (NHS, blue) and heat-inactivated human serum (HiS,
green) were used as controls. Negative values correspond with a decrease in
viable STm compared with starting normals. Samples were taken at minutes
45, 90, and 180 using a starting concentration of 106 CFU/ml. Sera from NI
(yellow) and STmOmpD immune (red) WT mice were tested. Data are
representative of two different experiments and represent the mean of 5–6
mice sera used. **P ≤ 0.01 assessed by two-tailed Mann–Whitney U test.
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within the protein, and found it mapped to the large surface-
exposed loop 6 on the outer rim of the OmpD trimer. Creation
of a homology model of the OmpD trimer revealed that A263 is
at the tip of the loop most distal from the hydrophobic core of
the membrane, and so potentially most accessible by anti-
body targeting OmpD (Fig. 4a). However, this site, on the outer
rim of the OmpD trimer, is next to the surrounding LPS O-Ag,
and thus antibody access to epitopes containing this residue
may be restricted due to a combination of LPS O-Ag occlusion
and the size of IgG antibodies. To examine the nature of
antibody–OmpD interaction on the surface of the bacterium,
we performed in silico analysis of the structures of OmpD, LPS,
and antibody (Fig. 4b–d). Strikingly, the diameter of the OmpD
trimer exceeds that of a Fab fragment (Fig. 4c: 70 Å for OmpD
trimer and ~50 Å for Fab along the shortest dimension). This
diameter of the OmpD trimer, and the associated LPS tunnel, is
not influenced by the A263S variation. We then performed
atomistic molecular dynamics (MD) simulations of the outer
membrane, which included explicit modeling of the LPS from
STm in two distinct random distributions of O-Ag length
between 6 and 11 repeats, for 2 μs per system (Fig. 4d; Sup-
plementary Fig. 3a). These simulations show that the LPS O-Ag
provides a robust barrier to prevent access to the cell envelope,
with each OmpD trimer tightly interacting with up to 15
molecules of LPS, greatly limiting the lateral mobility of OmpD
in the membrane. While the chains of O-Ag sometimes par-
tially occlude direct access in these simulations, their fluctua-
tions occasionally reveal an open pathway to the surface
(Fig. 4d). The prediction of accessibility of OmpD to IgG was
reinforced by a 70-ns steered MD simulation of full IgG
binding, which demonstrated that it can overcome the steric
hindrance of the O-Ag layer to reach the OmpD loops (Sup-
plementary Fig. 4). Furthermore, this simulation unequivocally
demonstrated that at most a single Fab fragment could be
accommodated within the footprint of the tunnel at a time.
Therefore, the size of the OmpD footprint explains how IgG
can gain access to the most-exposed surface loop epitopes of
OmpD in the presence of O-Ag.
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Fig. 3 Loss of O-Ag from SEn enhances protection by anti-STmOmpD antibodies. a IgG titers to STm and SEn WT and O-Ag-deficient mutants in sera
from NI mice and mice immunized with STmOmpD. b Serum bactericidal assays using STm D23580, SEn D24954, and STm and SEn wbaP− mutants with
sera from NI mice or mice immunized as in Fig. 1a, supplemented with human sera as a complement source with anti-STm-specific antibodies depleted.
Normal human serum (NHS, blue) and heat-inactivated human serum (HiS, green) were used as controls. Negative values correspond with a decrease in
viable STm compared with starting normals. Samples were taken at minutes 45, 90, and 180 using a starting concentration of 106 CFU/ml. Sera from NI
(yellow) and STmOmpD immune (red) WT mice were tested. c NI mice and mice immunized twice with 20 μg of STmOmpD were challenged with 1 × 105
of STm or SEn (WT or wbaP−) for 24 h, and bacterial burdens determined from the spleen, liver, and blood. Each point represents the titers from one
mouse. Data are from three different experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, NS= nonsignificant assessed by two-tailed
Mann–Whitney U test.
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O-Ag structure limits binding of anti-STmOmpD antibodies.
The previous experiments suggest a role for O-Ag in restricting
access to epitopes on OmpD. The O4 and O9 O-Ag expressed by
STm and SEn differ in their use of the sugars acetylabequose and
tyvelose within their O-Ag, respectively (Supplementary Fig. 3b).
Moreover, there is a strong correlation between the A263S
polymorphism and O-Ag usage by Salmonella in groups B and D
of the Kaufmann–White scheme (Supplementary Fig. 2). There-
fore, we examined whether different O-Ag can influence access to
epitopes on OmpD. To do this, we examined the level of binding
of anti-STmOmpD to STm, SEn, and to chimera strains of STm
and SEn engineered to express O9 and O4, respectively15. As
expected, strong binding of anti-STmOmpD antibody to WT
STm was detected, but antibody binding to WT SEn and both
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Fig. 4 Acessibility of OmpD epitopes is determined by the LPS component. OmpD structure and the location of the A263S polymorphism in the context
of interaction with the LPS layer. a OmpD trimer (homology model) with the location of the A263S variation (blue spacefill representation) on the tip of the
extracellular loop 6 (labeled L6, green in protomer 1). The other extracellular loops in this protomer are shown in different colors consistent with their
representation in Supplementary Figs. S2 and S6. b Snapshot of the full atomistic MD simulation of the outer membrane showing an isolated OmpD trimer
with a single LPS molecule. LPS elements are colored as follows: Lipid A—black; core sugars in red; O-Ag repeats in rainbow colors. c Size comparison of a
murine IgG1 molecule (based on PDB 1IGY) to the OmpD trimer and OmpA. Top shows an IgG1 molecule. The heavy chains are colored in green and gold,
while the light chains are in cyan and purple, respectively. Dimensions of various parts are indicated in Å. Bottom left, an OmpD trimer (protomers shown
in yellow, blue, and red) and bottom right an OmpA monomer (red). d A wider context of the MD system is shown from the membrane plane (left) and
from the top (right). OmpD protomers are colored in purple, red, and green, and LPS elements are colored as follows: Lipid A and inner leaflet in gray, core
sugars in gold, and O-Ag in dark blue. The dense network provided by the LPS O-Ag prevents access to the surface epitopes on OmpD, which is especially
clear on the spacefilling top-view representation on the right, showing a typical access channel dimension of 50 Å.
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chimeric strains was markedly reduced (Fig. 5a). Furthermore,
anti-STmOmpD antibody was only efficient at promoting the
killing of WT STm in a SBA (Fig. 5b), or after challenge of mice
immunized with STmOmpD (Fig. 5c). Moreover, after challenge
of STmOmpD-immunized mice with WT OmpD-expressing
STm, there was an approximately tenfold median reduction in
bacterial numbers, compared with a 3–4 median-fold reduction in
bacterial numbers after challenge with SEn or STm and SEn
mutants that express the reciprocal OmpD gene (i.e., STm
expressing OmpD 263S and SEn OmpD 263 A; Supplementary
Fig. 5). In combination, these results support the conclusion that
matched native O-Ag and OmpD are needed for optimal pro-
tection. As mentioned above, OmpD generates similarly sized
footprints and corresponding tunnel apertures in the LPS layer of
both serovars, despite the different O-Ag structures between STm
and SEn. However, we did observe a difference in the interactions
of extracellular loops 5, 6, and 8 of OmpD with LPS and O-Ag in
the STm and SEn simulations. The average contact area between
these loops and LPS was higher in both SEn systems compared
with the corresponding STm systems (Supplementary Fig. 6).
Despite a difference of just one sugar in the O-Ag of SEn
(O4, tyvelose) and that of STm (O9, acetylabequose) (Supple-
mentary Fig. 3b), the MD results suggest that this could account
for the former being more flexible than the latter (Supplementary
Fig. 7). These results highlight that O-Ag offers more than a
simple steric barrier to antibody, and that specific interactions
between the O-Ag and the protein component influence the
physical presentation of the epitope, impacting its availability
even when the antibody can access the antigen.
Antibodies to monomeric OmpA are not protective. If the
reason that OmpD induces protective antibodies is due to the
aperture size generated in the cell envelope by the trimer protein,
enabling access by antibody, then it could be expected that
antibodies to other cell wall antigens that generate smaller tunnels
would not be protective. OmpA has a similar molecular weight as
an OmpD monomer (35.4 kDa vs. 37.6 kDa, respectively)
(Fig. 4c). Unlike OmpD, OmpA does not typically form oligo-
mers in the outer membrane, and induces specific antibodies
rapidly after natural infection in mice and humans16. Using the
same structural approaches as before, we show that OmpA creates
a footprint that has an aperture that is too small for a Fab
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Fig. 5 O-Ag structure and variability influence access of antibody to OmpD. a IgG titers to STm and SEn WT and LPS chimera strains were assessed
using sera from NI mice and mice immunized with STmOmpD as in Fig. 1a. Each point represents the titers from one mouse. Representative of three
experiments. b Serum bactericidal assays using STm D23580, SEn D24954, and STm O9 and SEn O4 chimera mutants with sera from nonimmunized mice
(yellow) or mice immunized with STmOmpD (red) as in Fig. 1a, supplemented with human sera as a complement source with anti-STm-specific antibodies
depleted. Normal human serum (NHS, blue) and heat-inactivated human serum (HiS, green) were used as controls. Negative values correspond with a
decrease in viable STm compared with starting normals. Samples were taken at minutes 45, 90, and 180 using a starting concentration of 106 CFU/ml.
c Bacterial burdens from the spleens of NI and mice immunized twice with 20 μg of STmOmpD infected for 24 h with 1 × 105 of STm or SEn WT and O-Ag
chimeras. Data are representative of a minimum of two individual experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, NS= nonsignificant assessed by two-
tailed Mann–Whitney U test.
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fragment to access (Fig. 6a). Due to this occlusion, it is unlikely to
be a target of protective antibodies. Consistent with there being
less immunological pressure on this protein, we found that, unlike
OmpD, the OmpA sequence is identical between STm and SEn
isolates. We then purified OmpA to test the ability of antibodies
to OmpA to protect against natural infection in mice. Purified
OmpA was recognized rapidly by antibody-secreting cells
induced by natural infection of mice with STm and after
immunization of mice with purified OmpA (Fig. 6b). Never-
theless, antibody to purified OmpA bound only weakly to intact
bacteria, and did not induce protective responses (Fig. 6b, c).
Therefore, despite being a target of naturally induced antibodies,
this protein in STm and SEn is not under immune pressure, and
does not induce protective responses.
Discussion
Antibodies to STmOmpD protect against infection with STm12.
Since there is only a single amino-acid difference between OmpD
from STm and SEn, and anti-STmOmpD antibodies cross-react
with SEn, we hypothesized that immunization with STmOmpD
would protect against both STm and SEn. Unexpectedly, the level
of cross-protection, while statistically significant, was minimal in
terms of fold reduction in bacterial numbers. We show that this
lack of cross-protection is due to the complex relationship
between LPS O-Ag and OmpD.
O-Ag provides steric hindrance of antibody binding to the
bacterial surface. While the capacity of O-Ag to block antibody
access is well described in the literature17,18, the relationship
between O-Ag and other surface antigens is poorly understood.
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In the context of OmpD, O-Ag restricted access to conserved
epitopes that are proximal to the membrane surface. Conforma-
tional dynamics of LPS influence the behavior and presentation of
outer membrane proteins (OMPs)19–21, suggesting that surface
antigens need to be considered in the context of their native
environment. The LPS layer is one of the most complex mem-
brane environments and is notoriously difficult to replicate
in vitro. Up until recently, it was poorly understood, which
prevented even in silico approaches. Our work has been enabled
by recent breakthroughs in atomistic simulations, which now
permit explicit modeling of realistic outer membranes20,22–25.
Nevertheless, there are limitations to our modeling associated
with our incomplete understanding of the Gram-negative bac-
terial surface. For instance, although O-Ag chain length and
distribution have been studied in isolation, as has protein
clustering21,26, its effect in vivo and in the context of antibody
binding is unclear. Nevertheless, our modeling suggests that the
tunnel aperture size that is generated by the OmpD trimer in the
surrounding LPS layer is only sufficiently sized to accommodate
binding of a single Fab, and suggests that two independent
antibodies cannot bind an individual OmpD trimer concurrently.
An important and surprising implication of our results is that
despite only a single Fab being able to access the LPS channel, it
appears to be sufficient to promote complement-dependent kill-
ing. This conclusion is consistent with the experimental evidence
showing similar binding of anti-STmOmpD IgG to WT or O-Ag-
deficient STm and that bacterial outer-membrane vesicle vaccines
derived from bacteria lacking O-Ag can offer protection27. This
could indicate that it is not necessary to have both arms of an
antibody bound to a target antigen for it to be protective. Anti-
bodies to core oligosaccharide can be protective28. In this study, it
is not possible to rule out the possibility that antibodies generated
to the minimal core antigen co-purified with OmpD made some
contribution to the protection observed. Nevertheless, multiple
lines of evidence suggest that, if indeed present, any such con-
tribution is minimal. First, the levels of endotoxin in preparations
were minimal as assessed by limulus assay (< 2 EU/10 μg OmpD).
Second, mice are not protected after immunization with OmpD if
they are infected with an OmpD-deficient bacterium10. Third,
modification of the sequence of OmpD or the O-Ag expressed,
but retaining the same core antigen, resulted in reduced protec-
tion, which is inconsistent with antibodies to core antigen
accounting for the protection observed. Relatedly, the predicted
footprint generated by a single OmpD trimer in the LPS layer is
similar for STm and SEn, yet there is minimal cross-protection,
which is suggestive that anti-core antibodies make a minimal
contribution to the protection afforded by immunization with
purified OmpD.
Our studies show that although anti-STmOmpD sera recognize
multiple epitopes, in reality the presence of O-Ag translates to
protection being afforded by antibody binding to a restricted
number of epitopes that likely include the A263S polymorphism.
This means that, in terms of protection, not all epitopes are equal.
The protective potential of individual epitopes will be influenced
by the footprint of the antigen in the LPS layer, which has to be
sufficiently large to alleviate the occlusion by O-Ag and allow
access to its epitopes placing some epitopes under stronger
immunological pressure than others. This may explain the A263S
variation observed in loop 6 of OmpD, and is supported by the
cross-serovar conservation of OmpA. Our immunological data
are consistent with this interpretation, as it shows that antibody
to OmpA does not bind the bacterial surface nor is protective. At
the same time, our modeling predicts that the OmpA-generated
tunnel in the O-Ag is insufficiently sized to enable ready access by
antibody. Indeed, most published studies have not found pro-
tection after immunization with OmpA29,30. In one exception, a
study from Nikaido et al.31, protective monoclonal antibodies
against OmpA bound to a portion of OmpA that is only surface
exposed when OmpA adopts an atypical conformation that
results in a much larger footprint on the cell surface. This is
wholly consistent with the size of the tunnel being key for
enabling antibody access for binding and protection. Sequence
variation in the surface-exposed loops of other outer-membrane
proteins, such as the monomeric proteins OmpX and OmpW,
and the trimeric porin OmpC is similar to what we have
described here. OmpX and OmpW are identical between STm
and SEn, but there are differences in OmpC, which are conserved
between STm and SEn isolates, respectively, and thus may reflect
some association with O-Ag usage. In contrast, monomeric
OMPs do not appear to be under selective pressure to change.
These findings are consistent with the principles identified in this
study and could be predicted based on our findings with OmpD
and OmpA, correlating with the inability of the antibodies to
penetrate the narrow footprint created by monomeric porins.
An additional level of complexity is added by the diversity of
O-Ag structure, which can impede antibody binding to OmpD.
We show that antibody to OmpD to be protective then the O-Ag
must match the parent serovar of the OmpD. This dual
requirement was unexpected, but shows how antigens can com-
bine to enhance antigenic diversity. This was demonstrated most
clearly with the challenge experiments using chimaeric strains,
since the parent O-Ag and the A263S variation need to match for
the antibody to bind. This could explain why for Salmonella
within groups B and D of the Kauffmann–White scheme, there is
a close correlation between a specific O-Ag and the polymorph-
ism present in OmpD. Independently, modeling suggested that
differential O-Ag usage has an impact on the self-association of
O-chains, which may affect the nature of antibody interaction,
and by extension, the accessibility of the surface epitopes. This
observation adds another level of modulation, to the known
capacity of LPS to stabilize antigen conformation20,21.
Since O-Ag usage varies between many Gram-negative bac-
teria, our finding on the importance of the footprint made by
proteinaceous antigens and the relationship to immunological
protection has significant implications for vaccine design. Subunit
vaccines that protect against Gram-negative bacteria are typically
based on the surface capsular polysaccharide. There is no sin-
gle surface protein antigen subunit vaccine for Gram-negative
bacteria and if a capsule antigen is not used in the vaccine, then
they increase considerably in their complexity. One reason for
this increased complexity may be the influence of LPS/LOS O-Ag
on the accessibility of antibody to the component antigens,
meaning that greater antigen coverage is needed to ensure pro-
tection. In contrast, since capsules are typically located on the
outermost surface of the bacterium, it may mean there is less
impediment to antibody binding and less need to include mul-
tiple antigens in a vaccine.
One benefit from the shielding offered by O-Ag is to reduce the
immunological pressure to introduce base changes into a protein,
which could have fitness costs for the bacterium. To achieve a
single amino-acid change in OmpD requires as few as one
nucleotide change. In contrast, to alter O-Ag usage requires sig-
nificant changes in multiple genes involved in the biosynthetic
pathway. Nevertheless, the occlusion of antibody binding to the
bacterial surface by O-Ag reveals an intrinsic paradox as O-Ag
itself a target of protective antibodies, yet is not under the same
selective pressure within the same serovar. Although, the reasons
for this paradox are unclear, this may reflect our incomplete
understanding of the nature of antibody binding to the bacterium
or be due more to wholly unrelated reasons such as evading
attack by bacteriophages. Collectively, our results suggest that
merging structural modeling and immunology can predict which
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antigens, and the epitopes within those antigens, may be pro-
tective and such a priori knowledge may aid in development of
future vaccines against Gram-negative infections.
Methods
Bacterial strains, immunogens, mice, and immunizations. Invasive African
isolates S. Typhimurium D23580 and S. Enteritidis D249548,13, the virulent STm
SL1344 laboratory strain and the attenuated STm SL3261 aroA− and SEn P125109
aroA− were used in experiments32,33. Rough wbaP− STm D23580 and SEn
P125109 mutants, and STm O9 and SEn O4 LPS O-Ag chimera strains were kindly
provided by Dr Chris Coward (Cambridge)15. To generate STm D23580 or SEn
D29540 with chromosomal mutations so that STm expressed an OmpD with a
serine at amino-acid position 263, while SEn OmpD with an alanine at the same
position, an established protocol was used34. Using this, the positive–negative
selection cassette, encoding the kanamycin resistance marker and the rhamnose-
inducible relE toxin (kan-PrhaB-relE), was amplified from pSLC217 using oligo-
nucleotides containing the universal priming sites P1 and P2 with 50 bp of
homology to the centre of the ompD gene at the 5′ end of each primer (ompD-
KOpSLC217Fwd: 5′-GGCCTGGTTGAAGGTCTGAACTTTGCCGCGCAGTA
CCAGGGCAAAAACGACCGTGACTGT GTAGGCTGGAGCTGCTTC-3′ and
ompDKOpSLC217Rev: 5′-TCGTACTCATACGTTGCGGACAGACCGAAACC
GTCGCCGTTAGACTCGTACGCGCCGTCCATATGAATATCCTCCTTAG-3′.
The homology regions used were designed to insert the cassette into the middle of
ompD (nt 540 from the translation start site) without replacing any of the ompD
coding sequence. STm D23580 or SEn D29540 was transformed with the λ-RED
encoding plasmid pSIM18 by electroporation, and transformants were selected by
growth on LB agar supplemented with hygromycin (75 μg/ml) at 30 °C35. The
ompD flanked kan-PrhaB-relE cassette was then recombined into the chromosome
using established approaches34, except for the following modifications. Cells were
grown initially at 30 °C for 2 h after which λ-RED expression, from pSIM18, was
induced by temperature shift to 42 °C for 1 h before cells were made electro-
competent and transformed with the ompD flanked kan-PrhaB-relE cassette.
Recombinants were selected by growth on LB agar containing kanamycin (50 μg/
ml) at 37 °C. The presence of the kan-PrhaB-relE cassette was confirmed by PCR of
the ompD chromosomal locus followed by agarose gel electrophoresis. The ompD
gene was then amplified from STm D23580 or SEn D29540 and used in a second
round of recombineering, as described above, in order to replace the kan-PrhaB-relE
cassette disrupted ompD gene with the heterologous ompD gene. Recombinants
were selected by growth on M9 agar supplemented with 0.2% rhamnose. The
presence of the heterologous ompD gene in each strain was confirmed by PCR and
sequencing of the ompD chromosomal locus (ompDfwd: 5′-ATGAAACTT
AAGTTAGTGGCAGTG-3′ and ompDrev: 5′-TTAGAACTGGTAGTTCAG
ACCAACAG-3′). Strains were also checked for loss of the pSIM18 plasmid by
patch plating onto LB agar supplemented with hygromycin. Wild-type (WT)
C57BL/6 or CD1 mice between 6 and 12 weeks of age were used. Mice were
obtained from HO Harlan OLAC Ltd. (Bicester, UK) and from the Animal Facility
at the University of Cape Town (UCT). Mice were maintained under specific
pathogen-free conditions. Animal experiments were performed with full local
(University of Birmingham or University of Cape Town, Protocol 012-006) and
national ethical approval (for the UK compliance with the Animals (Scientific
Procedures) Act 1986 (project licences 30/2850 and P2E63AE7B). Mice were
infected intraperitionally (i.p.) as described for each experiment. OMPs were
purified by 2% (v/v) Triton X-100 extraction from bacterial pellets36. STmOmpD
(from OmpC and OmpF-deficient STm SL1344 or an OmpC, OmpF, and wbaP-
deficient mutant) and STm or SEn porins were purified by 2% (v/v) Triton X-100
extraction and repeated extraction with SDS and separation by fast protein liquid
chromatography on a Sephacryl S-200 column before dialysis against PBS/0.1% (w/v)
SDS in PBS10,12,37. The level of LPS detected in OmpD preparations by limulus
assay was typically ≤ 2 EU / 10 μg OmpD. Mice were immunized with 20 μg of
OmpD i.p. or PBS as described. For opsonization experiments, 5 × 105 bacteria/ml
were mixed for 30 min with individual heat-treated anti-STmOmpD sera or sera
from nonimmunized mice, diluted 1:100. Mice were then infected with 5 × 105
bacteria i.p. In each case, bacteria were cultured to confirm that the pre-
opsonization of bacteria did not induce clumping or affect viability.
Sequence analysis and homology modeling. The multiple sequence alignments
(MSA) were prepared using MAFFT and NJ/UPGMA phylogeny algorithms as
implemented in MAFFT v.7 server (https://mafft.cbrc.jp/)38, and Espript 339 was
used for visualization and structural annotations. For the purposes of homology
modeling which was based on the sequence of OmpD from Salmonella LT2
(Uniprot ID: P37592 (OMPD_SALTY)), we employed I-TASSER40 with manual
assignment of templates. We used OmpF from E.coli (1OPF.pdb)41, OmpC (5NUP:
A.pdb)42, and Osmoporin (Ompk36) from Klebsiella pneumoniae (1OSM.pdb)43 as
templates based on highest identity scores (63%, 64%, and 65% respectively), with
trimerization docking, local manual refinement and structural superposition per-
formed in Coot44. Figures were prepared using Pymol (The PyMOL Molecular
Graphics System, Version 1.71 Schrödinger, LLC) unless otherwise specified.
ELISA and serum bactericidal assays. Antibody specificity to STm and SEn
porins, STmOmpD, and whole organisms was tested by ELISA45. Plates were
coated with antigen at 5 μg/ml overnight. Mouse serum was added to wells with a
starting dilution of 1:50, then serially diluted and the presence of bound antibody
was detected with IgG-specific alkaline phosphatase (AP)-conjugated goat anti-
mouse antibody (Southern Biotech, catalogue 1015-04, dilution 1:2000) and
developed with Sigma FAST™ p-Nitrophenyl Phosphate tablets. Titers were cal-
culated by identifying the dilution at which the signal reached a set OD405.
Serum bactericidal assays were performed8, using human serum was used as a
complement source for murine antibodies14. Sera from mice immunized with
STmOmpD were supplemented with antibody-depleted human serum (1:2–1:18
dilutions from mice sera were made to give a final volume of 45 μl). A volume of 5
μl of Salmonella in logarithmic (log) growth phase (1 × 107 CFU/ml) per sample
was added to a v-bottomed 96-wells plate (Sarstedt). Heat-inactivated human
serum (HiS) was added in a 1:1 proportion with PBS as a negative control. Sera
from nonimmunized mice were used as controls. Samples were incubated at 37 °C
on a rocker plate with shaking at 20 rpm, and samples plated in triplicate on agar
plates 45, 90, and 180 min after incubation. Growth or killing of the bacteria was
represented graphically by transforming the data into log10.
MD simulations. The OmpD trimer from STm or SEn was placed in a corre-
sponding outer membrane model that included an outer leaflet of LPS molecules and
an inner leaflet composed of 75% POPE and 25% POPG lipids, built using VMD46.
The length of the O-Ag chain of each LPS molecule was randomly assigned to be
between 6 and 11 repeating units. Because LPS diffusion is too slow to avoid bias
due to the initial distribution in simulations20,47, two models with different random
distributions were constructed for each serovar. An alternative approach is to use
coarse-grained simulations, which can reach 1–2 orders-of-magnitude longer time
scales48–50. Since each LPS molecule is negatively charged (−12), Mg2+ and Ca2+
ions were added to neutralize the system (236 and 52 for the A systems, respectively,
and 241 and 47 for the B systems, respectively). Next, Na+ and Cl− ions were added
to bulk solvent to a concentration of 150mM, resulting in a system size of ~300,000
atoms. Each of the four systems (two for STm and two for SEn) was run for 1 μs,
followed by two 500-ns replicas that were used for analysis (2 μs of simulation for
each of the four systems). The simulations were performed using NAMD51 and
Amber1652 along with the CHARMM36 force field53,54 in the NPT ensemble at a
temperature of 310 K and a pressure of 1 atm. A 2-fs time step was used for the first
250 ns, after which hydrogen mass repartitioning (HMR) was employed to reach a
time step of 4 fs for the remainder of the simulations. HMR has recently been
demonsrated to be applicable to membrane-protein systems with little to no effect on
dynamics55. For the steered MD simulation, a murine IgG1 antibody (taken from
PDB 1IGY) was added to the STm-B system and pulled towards the OmpD loops at
1.0 Å/ns for 70 ns.
Convergence of the simulations was judged by monitoring the membrane
area and the RMSD of the OmpD trimer, both of which were stabilized within
1 μs in most cases (see Supplementary Figs. 8 and 9, respectively). The time scale
required is similar to that observed in previous simulations of outer
membranes56,57. Finally, although the LPS does not diffuse on the time scale of
our simulations, the O-Ag have greater freedom of movement, as shown in
Supplementary Fig. 7.
Statistical analysis. Data were analyzed using GraphPad Prism Version 6.0.
Differences in nonparametric data were determined with the Mann–Whitney U
test. For SBA data, the Mann–Whitney U test was used to determine the difference
in growth at 180 min between immune and non-immune mice sera.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
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